Skip to content

Inventories at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$3.36B-9.8%
Danaher logo
DanaherDHR
$2.61B+3.0%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$53.49M-28.4%
TEC
Bio-TechneTECH
$201.18M+5.3%
Revvity logo
RevvityRVTY
$387.51M+1.6%
Agilent Technologies logo
Agilent TechnologiesA
$1.09B+9.9%

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%
Net margin-36.2%
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InventoryGross.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s inventories?
Cytek Biosciences, Inc. (CTKB) reported inventories of $49.79M in Q1 2026.
How has Cytek Biosciences, Inc.'s inventories changed year-over-year?
Cytek Biosciences, Inc.'s inventories increased by 9.8% year-over-year, from $45.35M to $49.79M.
What is the long-term trend for Cytek Biosciences, Inc.'s inventories?
Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s inventories has grown at a 21.3% compound annual growth rate (CAGR), from $89.95M to $194.91M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.